Jeena Sikho Lifecare to acquire 51% stake in UAE's Back to Roots Ayurveda for AED 1.53M
Jeena Sikho Lifecare, through its subsidiary, will acquire a 51% stake in UAE-based Back to Roots Ayurveda by Dr. Shyam LLC. The acquisition, valued at AED 1,530,000 (approx. ₹3.5 crore), aims to expand JSLL's footprint in the Ayurveda and wellness sector internationally. The deal is expected to conclude in 2-3 months.
The acquisition is strategic for expanding into international markets and the Ayurveda segment, but the value of the acquisition (AED 1.53 million) is relatively small compared to the overall size of a listed company, suggesting a medium impact.
The acquisition of a controlling stake in an international Ayurveda company is a strategic growth move, indicating expansion and potential for increased revenue and market share.
Jeena Sikho Lifecare Limited (JSLL) has announced a strategic move to strengthen its presence in the Ayurveda and wellness segment. Through its wholly owned subsidiary, Jeena Sikho International LLC, the company will acquire a 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC, based in Abu Dhabi, UAE.
The decision was approved by the Board of Directors of Jeena Sikho International LLC on January 7, 2026. The acquisition is planned to be executed via a Share Purchase Agreement, which is yet to be finalized. Upon completion, Back to Roots Ayurveda will become a step-down subsidiary of JSLL.
This acquisition aligns with JSLL's broader strategy to explore international business opportunities and leverage the target entity's established operations and market presence. The company expects this move to contribute to its long-term growth and value creation. The transaction involves a cash consideration of AED 1,530,000 (approximately ₹3.5 crore). The acquisition is anticipated to be completed within approximately 2 to 3 months from the announcement date.
Back to Roots Ayurveda is recognized in the UAE for its doctor-led Ayurvedic care, blending classical wisdom with modern approaches. Incorporated on December 15, 2023, its reported turnover was AED 2,506,465 in 2025 and AED 776,600 in 2024. This acquisition is not considered a related party transaction.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.